PDCD1 and hepatocellular carcinoma: Phase I/II trials of PD-1 inhibitor monotherapy, nivolumab or pembrolizumab, in advanced hepatocellular carcinoma (HCC) have shown clinically significant response rates (17–20%)7,8.